Devices, digital health, and the technology changing how care is delivered.
As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its bid to expand the reach of its mRNA platform to the massive influenza vaccination market.
Insilico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune disorders in a deal that could be worth more than $2.5 billion.
Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five months to forge, but not without undergoing some stress tests.
Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring Paulo Fontoura, M.D., Ph.D., to replace Houman Ashrafian, Ph.D., as the head of the company’s stuttering R&D group.
Bionyra is emerging from stealth with an oversubscribed Series A round of $165 million co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures also participated in the round after the company received seed financing from Sofinnova Partners.
Biopharma development has long trended toward specialized and personalized therapies such as cell and gene therapies, antibody-drug conjugates, and monoclonal antibodies (mAbs), among others.
AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.
French biopharma Sanofi inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD) that will be distributed to select healthcare systems and low-income community care clinics.
Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.
In another sign that the FDA is easing its stance toward rare disease drug candidates under new leadership, the agency will reconsider Regenxbio’s gene therapy for an ultra-rare childhood disease, a reversal coming just about four months after a rejection.
Virtual control groups are redefining study design—cutting animal use while advancing rigor and regulatory momentum.
The FDA has sent out an early alert to J&J’s Abiomed unit and its manufacturing partner, Oscor, for their catheter introducer kits that are used with Impella heart pumps amid manufacturing concerns.
With a balance of competitive efficacy and tolerability, Corxel figures it has a potential winner to take into late-stage development.
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and more continue to dog the industry, even as pipelines bring massive sales opportunities to bear.
Merck KGaA has committed $50 million to build a new biotech with prolific life science investor Versant Ventures, with the ultimate goal of devouring the NewCo down the line.
Eli Lilly and Astellas have emerged as “stalking horse bidders” for certain assets as part of Sangamo’s bankruptcy process.
The focus of the company is SERP-01, an in vivo base editing program targeting AATD developed in China and licensed from YolTech Therapeutics.
An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch of new companies to fly its drug candidates forward.
Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple targets.
Omnipod maker Insulet has hired Divakar Ramakrishnan, Ph.D., as its new Chief Research and Development Officer.
On Tuesday afternoon at the 2026 Biotechnology Innovation Organization conference in San Diego, Flagship Pioneering announced a research collaboration with Lean Business Services within the well-appointed Saudi Arabia pavilion in the heart of the conference’s exhibition floor.
Access Vascular, a Massachusetts-based device maker that focuses on intravenous catheters, inked a partnership deal with medical supply giant Medline to help roll out a new line of catheters.
Abbott has become the latest company to team up with Alzheimer’s disease blood test developer ALZpath.
Novartis is paying Antares Therapeutics $105 million upfront in a deal worth up to $1.9 billion to generate small molecules against historically undruggable oncology targets.